期刊文献+

高效液相色谱-串联质谱法测定人血浆中氯法拉滨的浓度 被引量:5

Determination of Clofarabine in Human Plasma by LC-MS/MS
原文传递
导出
摘要 目的建立高效液相色谱-串联质谱法(LC-MS/MS)测定人血浆中氯法拉滨浓度。方法采用API3000串联质谱仪及Shimadzu系列液相色谱仪进行检测。血浆样品经乙酸乙酯提取处理,以克拉屈滨为内标。色谱柱为ThermoC18柱(4.6mm×150mm,5μm),流动相为乙腈-水(250∶3,其中含4mmol的乙酸铵和0.3%的甲酸),流速为0.5mL.min-1。氯法拉滨和克拉屈滨的MRM扫描离子通道m/z分别为304.0→170.0,286.1→170.0。进样体积为20μL,每个样品的分析时间为5min。结果氯法拉滨和克拉屈滨保留时间分别为4.00,4.11min。氯法拉滨在10~2000ng·mL-1内线性关系良好(r=0.9995),日内、日间RSD均低于9.60%,准确度为101.10%~102.94%。结论本法样品预处理简便快速,检测准确、灵敏、专一,适用于氯法拉滨药动学的研究。 OBJECTIVE To establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of clofarabine in human plasma. METHODS The drug was determinated by LC-MS/MS using electrospray ionization. The plasma samples were extracted with ethyl acetate. Cladribine was the internal standard (IS). The analytical column was Thermo C18 column (4.6 mm×150 mm,5 μm). The mobile phase consisted of acetonitrile-water (250:3,Which contains 4 mmol of ammonium acetate and 0.3% formic acid) at a flow rate of 0.5 mL·min-1. Clofarabine and cladribine were detected on multiple reaction monitoring (MRM) by the transitions from the precursor to the product ion (m/z 304.0/170.0 and m/z 286.1/170.0). The injection volume was 20 μL and the total run time was 5.0 min. RESULTS Calibration curve showed good linearity in the range of 10-2 000 ng·mL-1 (r=0.999 5). The intra-batch and inter-batch precisions (RSD) were all less than 9.60% and the accuracy was within 101.10%-102.94%. CONCLUSION The retention time of cladribine and clofarabine were 4.00 and 4.11 min. The established LC-MS/MS method is sensitive,accurate and simple for the determination of clofarabine in human plasma. It is suitable for the pharmacokinetics of clofarabine.
出处 《中国药学杂志》 CAS CSCD 北大核心 2010年第19期1496-1499,共4页 Chinese Pharmaceutical Journal
关键词 氯法拉滨 高效液相色谱-串联质谱法 血浆浓度 clofarabine LC-MS/MS drug plasma concentration
  • 相关文献

参考文献5

  • 1赵珺,陈祥峰.毛细管气相色谱法检测氯法拉滨中的残留溶剂[J].药学与临床研究,2008,16(4):330-332. 被引量:4
  • 2聂颖兰,傅得兴,胡欣,王唯红.新型抗白血病药氯法拉滨[J].中国新药杂志,2007,16(10):821-824. 被引量:9
  • 3JUDITH E K, REBECCA M R, KUMUDHA B, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias [ J ]. Clin Trials Observations, 2007, 110(6) : 1762 - 1769.
  • 4YUNSHENG H, CHRISTINE J G D, SUINING L. et al. Comparision of fast liquid chromatography/tandem mass spectrometric methods for simultaneous determination of cladribine and clofarabine in mouse plasma [J] . J Pharm Biota Anal, 2007, 44(2) : 492 - 497.
  • 5VARSHA G, HAGOP K, STEFAN F, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias[ J ]. Clin Cancer Res, 2003, 9(12): 6335 -6342.

二级参考文献22

  • 1王蔚,晋展.抗急性白血病新药Clofarabine[J].药学进展,2004,28(7):336-336. 被引量:10
  • 2聂颖兰,傅得兴,胡欣,王唯红.新型抗白血病药氯法拉滨[J].中国新药杂志,2007,16(10):821-824. 被引量:9
  • 3夏敏,蒋慧.儿童急性白血病治疗新药氯法拉滨[J].世界临床药物,2007,28(6):356-359. 被引量:11
  • 4国家药典委员会 二部.中华人民共和国药典[S].北京:化学工业出版社,2005.附录.
  • 5FADERL S, GANDHI V, O'BRIEN S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine ( ara-C ) in relapsed and refractory acute leukemias [ J ]. Blood, 2005, 105(3) :940-947.
  • 6FADERL S,VERSTOVSEK S,CORTES J,et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia(AML) in patients 50 years of age or older[J]. Blood,2006 ,108(1) :45 -51.
  • 7KERSEY JH. Fifty years of studies of the biology and therapy of childhood leukemia [ J ]. Blood, 1997,90 ( 11 ) : 4243 - 4251.
  • 8SADOWITZ PD, SMITH SD, SHUSTER J, et al. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia:a Pediatric Oncology Group study[J]. Blood ,1993,81( 3 ) :602 - 609.
  • 9STAHNKE K, BOOS J, BENDER-GOTZE C, et al. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia[J]. Leukemia, 1998,12(10) :1534 - 1538.
  • 10BONATE PL, ARTHAUD L,WILLIAM R. Discovery and development of elofarabine : a nueleoside analogue for treating cancer[J]. Nat Rev Drug Discov, 2006,5(10) : 855 -863.

共引文献8

同被引文献29

  • 1陈莉莉,岑均达.克拉屈滨的合成[J].中国医药工业杂志,2005,36(7):387-389. 被引量:6
  • 2聂颖兰,傅得兴,胡欣,王唯红.新型抗白血病药氯法拉滨[J].中国新药杂志,2007,16(10):821-824. 被引量:9
  • 3夏敏,蒋慧.儿童急性白血病治疗新药氯法拉滨[J].世界临床药物,2007,28(6):356-359. 被引量:11
  • 4Judith E, Rebecca M, Kumudha B, et aL A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias [J]. Clinical Trials and Observations, 2007,110(6 ) 1 762.
  • 5Hsieh Y, Christine J, Lee S, et al. Comparision of fast liquid chromatography]tandem mass spectrometric methods for simultaneous determination of cladribine and clofarabine in mouse plasma[J]. Journal of Pharmaceutical and Biomedical Analysis, 2007,44 (5) : 492.
  • 6Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias [J]. Clin Cancer Res, 2003,9 (17) : 6 335.
  • 7Lech-Maranda E, Korycka A, Robak T. Clofara- bine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity[J]. Mini Rev Med Chem,2009,9(7) -805-812.
  • 8Qian M, Wang X, Shanmuganathan K, et al. Pharmacokinetics of the anticancer agent 2-chloro-9 (2- deoxy-2fluoro-beta-D-arainofuranosyl ) adenine in rats[J]. Cancer Chemother Pharmacol, 1994, 33 (6):484-488.
  • 9Bonate PL, Arthaud L, Stuhler J, et al. The distribution, metabolism, and elimination of clofarabine in rats[J].Drug Metab Dispos,2005,33(6):739- 748.
  • 10Bonate PL, Arthaud L, Cantrell WRJr, et al. Dis-covery and development of clofarabine , a nucleoside analogue for treating cancer[J]. Nat Rev Drug Dis-cov , 2006, 5(10) :855-863.

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部